The long-term effect of Medical HAL for ALS

CYBERDYNE Inc. (Tsukuba, Ibaraki, Japan, President & CEO: Yoshiyuki Sankai, from now on referred to as the “Company”) announced today that an international journal on the HAL for Medical Use Lower Limb Type (hereafter “Medical HAL”) had been published by Toho University School of Medicine Department of Neurology in Internal Medicine*1 published. In this journal, the research group from Toho University School of Medicine reported on a one-year Cybernics Treatment*2 using Medical HAL for patients with Amyotrophic Lateral Sclerosis (“ALS”). In this progressive neurodegenerative disease, improvement of muscle weakness cannot be expected with therapeutic drugs and other means, although some can inhibit the progression. All three patients showed an effect of maintaining their walking function with HAL Cybernics Treatment. The average 2-minute walking distance remained at the same level as before the start of treatment at 300 days. Clinical trials have shown the efficacy of treatment with Medical HAL for eight types of progressive neuromuscular diseases, including ALS, which led to coverage of such treatment with public health insurance. However, this paper is an important achievement in the medical industry because it demonstrates the effectiveness of the treatment over a period of one year.

 The research group that conducted this study included Assistant Professor Harumi Morioka (tenured), Lecturer Takehisa Hirayama, Professor Osamu Kano of the Department of Neurology, Toho University School of Medicine and Professor Satoru Ebihara of the Department of Rehabilitation Medicine, published a paper on March 17, 2022, regarding short-term (one to two months) Cybernics Treatment using a medical HAL for ALS patients. The Company notes that the difference with the journal posted on this occasion is that the relevant journal investigated the long-term effect (one year).

Links worth following:
1)【News】Journal published on the long-term effect of Medical HAL for ALS - CYBERDYNE
2) https://www.jstage.jst.go.jp/article/internalmedicine/61/10/61_8030-21/_pdf/-char/ja

Nasi partnerzy

fundusze unijne, contance care